|
|
|
|
|
|
|
09.02.26 - 03:06
|
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer′s Disease Designated for Priority Review in China (GlobeNewswire EN)
|
|
|
TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, which was accepted in January 2026, has been designated for Priority Review by the National Medical Products Administration (NMPA) of China....
|
|
|
|
|
|
|
06.02.26 - 10:06
|
Fosun Pharma′s US$1.55 billion Eisai deal signals shift to long-term partnerships (SCMP)
|
|
|
A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan's Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development.
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners, shifting from simple one-off licensing fees, where a company is paid for granting rights to its drug, to long-term collaborations.
Under......
|
|
|
|
|
|
|
27.01.26 - 11:48
|
FDA to review Eisai′s Leqembi Iqlik sBLA for Alzheimer′s (PBR)
|
|
|
The submission relates to patients with mild cognitive impairment or mild dementia due to Alzheimer's. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date
The post FDA to review Eisai's Leqembi Iqlik sBLA for Alzheimer's appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
|
|
21.01.26 - 08:00
|
Research: Bernstein Lists Top Picks in Asia-Pacific for 1H26 (Table) (AAStocks)
|
|
|
CNOOC (00883.HK)JD.com (JD.US) (09618.HK)SK hynix (000660.KS)Samsung Electronics (005930.KS)Tokyo Electron (8035.JP)Kokusai (6525.JP)Renesas (6723.JP)Power Finance (POWF.IN)Record plc (RECL.IN)Daiichi Sankyo (4568.JP)Eisai Co (4523.JP)Rio Tinto (RIO.AU)Piotech (688072.SH)MediaTek (2454.TW)Tianqi Lithium (002466.SZ) (09696.HK)Doo......
|
|
|
07.01.26 - 07:03
|
Corporate News: Newron Pharmaceuticals S.p.A. (EQS)
|
|
|
Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan...
|
|
|
06.01.26 - 12:24
|
BLA for subcutaneous formulation of Leqembi® accepted in China (PR Newswire)
|
|
|
STOCKHOLM, Jan. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for treatment of early Alzheimer's......
|
|
|
17.12.25 - 00:30
|
China′s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms? (SCMP)
|
|
|
Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable.
Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
